HONG KONG – Catching up with international markets, China is unbinding its drug manufacturing licensing regime from the marketing authorization in a move aimed at revolutionizing the country's drug development space.

HONG KONG – Three years after a failed attempt, Chinese insulin maker Gan & Lee Pharmaceuticals Ltd. is looking at China's stock markets.

HONG KONG – Catching up with international markets, China is unbinding its drug manufacturing licensing regime from the marketing authorization in a move aimed at revolutionizing the country's drug development space.